Results 41 to 50 of about 101,700 (245)

Development of imatinibmesylate-induced interstitial lung disease 2 weeks after discontinuation of the treatment: a case report

Multidisciplinary Respiratory Medicine, 2012
Background Imatinibmesylate (imatinib) is a small molecule tyrosine kinase inhibitor administered to patients with chronic myelogenous leukemia and gastrointestinal stromal tumor.
Nakashima Shota, Kakugawa Tomoyuki, Motomura Hiroko, Hirano Katsuji, Sasaki Eisuke, Nagata Yasuhiro, Kinoshita Akitoshi, Sakamoto Noriho, Ishimatsu Yuji, Mukae Hiroshi, Kohno Shigeru   +10 more
doaj   +1 more source

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia [PDF]

, 2014
Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. Although mechanisms of BCR/ABL1-induced transformation are well-defined, little is known about effector-molecules contributing to malignant expansion and ...
Bilban, Martin, Blatt, Katharina, Cerny-Reiterer, Sabine, Herndlhofer, Susanne, Herrmann, Harald, Hoermann, Grego, Holyoake, Tessa L., Mannhalter, Christine, Mayerhofer, Matthias, Rulicke, Thomas, Sadovnik, Irina, Sperr, Wolfgang R., Stefanzl, Gabriele, Streubel, Berthold, Valent, Peter, Willmann, Michael   +15 more
core   +1 more source

The chronic myeloid leukemia stem cell: stemming the tide of persistence [PDF]

, 2017
Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a ...
Holyoake, Tessa L., Vetrie, David
core   +1 more source

Antileukemic Activity of hsa-miR-203a-5p by Limiting Glutathione Metabolism in Imatinib-Resistant K562 Cells

Current Issues in Molecular Biology, 2022
Imatinib has been the first and most successful tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML), but many patients develop resistance to it after a satisfactory response. Glutathione (GSH) metabolism is thought to be one of the factors
Priyanka Singh, Radheshyam Yadav, Malkhey Verma, Ravindresh Chhabra   +3 more
doaj   +1 more source

Two different point mutations in ABL gene ATP-binding domain conferring Primary Imatinib resistance in a Chronic Myeloid Leukemia (CML) patient: A case report

Biological Procedures Online, 2004
Imatinib (Gleevec) is the effective therapy for BCR-ABL positive CML patients. Point mutations have been detected in ATP-binding domain of ABL gene which disturbs the binding of Gleevec to this target leading to resistance.
Iqbal Zafar, Siddiqui Rubina T., Qureshi Javed A.   +2 more
doaj   +1 more source

Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics

Frontiers in Pharmacology, 2020
Long-term use of imatinib is effective and well-tolerated in children with chronic myeloid leukaemia (CML) yet defining an optimal dosing regimen for imatinib in younger patients is a challenge.
Jeffry Adiwidjaja, Alan V. Boddy, Alan V. Boddy, Andrew J. McLachlan   +3 more
doaj   +1 more source

Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression. [PDF]

, 2016
Gastrointestinal stromal tumors (GIST) arise within the interstitial cell of Cajal (ICC) lineage due to activating KIT/PDGFRA mutations. Both ICC and GIST possess primary cilia (PC), which coordinate PDGFRA and Hedgehog signaling, regulators of ...
Bardsley, Michael R, Burgoyne, Adam M, Chan, Jonathan C, Chmielecki, Juliann, Gao, Fei, Harismendy, Olivier, Kendrick, Michael L, Lee, Tracy E, Leonard, Stephanie Y, Mao, Junhao, Morosini, Deborah, Ordog, Tamas, Ross, Jeffrey S, Shi, Eileen, Sicklick, Jason K, Siena, Martina De, Syed, Sabriya A, Tang, Chih-Min, Wang, Kai   +18 more
core   +2 more sources

Paraneoplastic hypoglycaemia secondary to IGF-2 secretion from a metastatic gastrointestinal stromal tumour [PDF]

, 2020
We report the case of a 79-year-old male with previous history of non-Hodgkin's lymphoma in remission, who presented acutely to the Accident and Emergency department with recurrent episodes of hypoglycaemia.
Dimitriadis, Georgios K., Drakou, Eftychia E., Ganguly, Ratnadeep, Giovos, Georgios, Grossman, Ashley B., Kosmas, Christos, Leca, Bianca, Murthy, Narasimha, Onyema, Michael C., Randeva, Harpal S.   +9 more
core   +1 more source

Nanobody‐Conjugated Theranostic Prodrug Targeting αvβ3 Integrin Enables Precision Cancer Therapy With Real‐Time Imaging

Advanced Healthcare Materials, EarlyView.
The image shows a schematic form a nanobody‐conjugated theranostic prodrug (NBD) platform targeting tumor‐associated αvβ3 integrin. The NBD system integrates selective nanobody‐mediated tumor recognition, glutathione‐responsive disulfide cleavage for doxorubicin release, and aza‐BODIPY‐based near‐infrared fluorescence for real‐time imaging.
Sanu Karan, Hyunseung Lee, Rema Naskar, Mi Young Cho, Hye Sun Park, Eun Hee Han, Soumyadip Hore, Sun Hee Cho, Truc Ngoc Kim Lam, Taewoong Son, Tae Jung Park, Inkyu Hwang, Jonathan L. Sessler, Kwan Soo Hong   +13 more
wiley   +1 more source

Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS [PDF]

, 2011
The LC-ESI-MS was developed and validated for the analysis of imatinib in plasma and bone marrow samples using deuterated imatinib (D(8)-IM) as an internal standard. The biological samples were extracted using Strata-X-C SPE cartridges and separated on C&
Elliott, M., Holyoake, T.L., Iqbal, Z., Jorgensen, H.G., Watson, D.G.   +4 more
core   +1 more source